The DOI matches its Crossref record.
Long-Term Survival After Cisplatin-Based Induction Chemotherapy and Radiotherapy for Nasopharyngeal Carcinoma: A Pooled Data Analysis of Two Phase III Trials
Open accessAbstract
Purpose: To evaluate the long-term outcome in patients with nasopharyngeal carcinoma (NPC) treated with induction chemotherapy and radiotherapy (CRT) versus radiotherapy alone (RT). Patients and Methods: The data from two phase III studies comparing CRT with RT in NPC were updated and pooled together for analysis. A total of 784 patients were included for analysis, with an equal number of patients in both arms. Induction chemotherapy consisted of two to three cycles of cisplatin, bleomycin, and fluorouracil, or cisplatin and epirubicin. RT was given to the nasopharynx and neck using megavoltage radiation (median dose, 70 Gy). The median follow-up time for surviving patients was 67 months. Analysis was based on intention to treat. Results: The addition of induction chemotherapy to RT was associated with a decrease in relapse by 14.3% and cancer-related deaths by 12.9% at 5 years. The 5-year relapse-free survival rate was 50.9% and 42.7% in the CRT and RT arm, respectively (P = .014), and the 5-year disease-specific survival rate was 63.5% and 58.1% in the CRT and RT arm, respectively (P = .029). The 5-year overall survival rate was 61.9% and 58.1% in CRT and RT arm, respectively (P = .092). The incidence of locoregional failure and distant metastases was reduced by 18.3% and 13.3% at 5 years, respectively, with induction chemotherapy. There was no significant difference in the treatment failure patterns between the two arms. Conclusion: The addition of cisplatin-based induction chemotherapy to RT was associated with a modest but significant decrease in relapse and improvement in disease-specific survival in advanced-stage NPC. However, there was no improvement in overall survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Chen, Y.-P., Chan, A. T. C., Le, Q.-T., Blanchard, P., Sun, Y., & Ma, J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30956-0 · Cited by 3,077
Self-citationNasopharyngeal carcinoma: an evolving paradigm
Wong, K. C. W., Hui, E. P., Lo, K.-W., Lam, W. K. J., Johnson, D., Li, L., Tao, Q., Chan, K. C. A., To, K.-F., King, A. D., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00524-x · Cited by 546
Hui, E. P., Ma, B. B., Leung, S. F., King, A. D., Mo, F., Kam, M. K., Yu, B. K., Chiu, S. K., Kwan, W. H., Ho, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1545 · Cited by 523
Tang, L., Chen, Y., Chen, C., Chen, M., Chen, N., Chen, X., Du, X., Fang, W., Feng, M., Gao, J., et al. (2021) · Cancer Communications · doi:10.1002/cac2.12218 · Cited by 413
Self-citationChen, Y.-P., Ismaila, N., Chua, M. L. K., Colevas, A. D., Haddad, R., Huang, S. H., Wee, J. T. S., Whitley, A. C., Yi, J.-L., Yom, S. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03237 · Cited by 390
Self-citation
Metadata
- Authors
- Chua, D. T. T., Ma, J., Sham, J. S. T., Mai, H.-Q., Choy, D. T. K., Hong, M.-H., Lu, T.-X., & Min, H.-Q.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-02-20
- Volume
- 23
- Issue
- 6
- Pages
- 1118-1124
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2005374110
- Cited by
- 242
- References
- 0
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Term Survival After Cisplatin-Based Induction Chemotherapy and Radiotherapy for Nasopharyngeal Carcinoma: A Pooled Data Analysis of Two Phase III Trials. https://app.cochat.ai/papers/10.1200/jco.2005.12.081
- The paper
- Chua, D. T. T., Ma, J., Sham, J. S. T., Mai, H.-Q., Choy, D. T. K., Hong, M.-H., Lu, T.-X., & Min, H.-Q. (2005). Long-Term Survival After Cisplatin-Based Induction Chemotherapy and Radiotherapy for Nasopharyngeal Carcinoma: A Pooled Data Analysis of Two Phase III Trials. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.12.081
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.